
CRS News
Carpenter Technology Corporation
$271.68
+$2.00(+0.74%)
45
Overall
40
Value
18
Tech
78
Quality
Market Cap
$13.46B
Volume
745.67K
52W Range
$270.49 - $625.99
Target Price
$421.25
CRS news: the latest Carpenter Technology Corporation headlines, press releases and market updates, newest first.
Latest CRS News
- Aclaris Advances Modzatinib Trial in Lichen Planus: What ACRS Investors Should KnowTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 18, 2026
- H.C. Wainwright Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)TipRanks Auto-Generated Intelligence Newsdesk · Nov 16, 2026
- Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), GH Research (GHRS) and Lantheus (LNTH)TipRanks Newsroom · Nov 16, 2026
- Corsair Gaming Earnings Call Signals Stronger Growth AheadTipRanks Auto-Generated Newsdesk · Nov 13, 2026
- CRISPR Therapeutics Advances Gene-Editing Trial for High Blood PressureTipRanks Clinical-Trials-Auto-Generated Newsdesk · Nov 12, 2026
- Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), COMPASS Pathways (CMPS) and Zenas BioPharma, Inc. (ZBIO)TipRanks Newsroom · Nov 9, 2026
- Wedbush Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)TipRanks Auto-Generated Intelligence Newsdesk · Nov 9, 2026
- Oppenheimer Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)TipRanks Auto-Generated Intelligence Newsdesk · Nov 6, 2026
- Caprice Declares Maiden High-Grade Resource at Island Gold ProjectTipRanks Australian Auto-Generated Newsdesk · Nov 4, 2026
- Caprice Establishes High-Grade Foundation With 522,000-Ounce Island ResourceTipRanks Australian Auto-Generated Newsdesk · Nov 4, 2026
- Crispr Therapeutics AG (CRSP) Receives a Hold from RBC CapitalTipRanks Auto-Generated Intelligence Newsdesk · Nov 4, 2026
- Caprice Reports 522,000-Ounce Maiden Resource at IslandTipRanks Australian Auto-Generated Newsdesk · Nov 3, 2026
- Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)TipRanks Newsroom · Nov 3, 2026
- Crispr Therapeutics AG (CRSP) Receives a Buy from Piper SandlerTipRanks Auto-Generated Intelligence Newsdesk · Nov 3, 2026
- Icarus Capital Appoints Strategic Advisor, Grants Stock OptionsTipRanks Canadian Auto-Generated Newsdesk · Nov 2, 2026
- Oppenheimer Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS)TipRanks Auto-Generated Intelligence Newsdesk · Oct 28, 2026
- Aclaris Therapeutics Announces New $46.7M Equity OfferingTipRanks Auto-Generated Newsdesk · Oct 27, 2026
- Aclaris Highlights Positive ATI-052 Trial and Strong LiquidityTipRanks Auto-Generated Newsdesk · Oct 27, 2026
- Caprice shareholders back placement and director incentives at general meetingTipRanks Australian Auto-Generated Newsdesk · Oct 23, 2026
- Crispr Therapeutics Expands Into Autoimmune Neurology With New CTX112 TrialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 22, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRS | $271.68 | +0.7% | 745.67K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Carpenter Technology Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW